Biarritz International Congress

Sterilization / Combination Products / Premises

When ?

13, 14 & 15 October

Where?

Bellevue Convention Center, Biarritz

Format?

Conferences, workshops & exhibition

The 37th A3P International Congress will take place on October 13, 14, and 15, 2026 in Biarritz. As it does every year, the event brings together the entire profession to guide the healthcare industries from the fundamentals to advanced expertise, while maintaining their competitiveness.

For this 2026 edition, A3P would like to share with you testimonials and insights that fall under the following three major themes:

Facility management, the foundation of industrial quality and product safety.
Sterilization processes, a fundamental step in the manufacture of sterile products.
Combination product, at the intersection of pharmaceuticals and medical devices, subject to a demanding regulatory framework.

Over these three days, through 15 conferences, you will discover concrete examples of how regulatory and environmental challenges are transformed into industrial excellence, positioning people as an indispensable strategic lever. The sessions will demonstrate how innovation enables us to meet the complex challenges of production to ensure the availability of medicines worldwide.

You will participate in workshops (20 workshops available) led by experts and discover an exhibition featuring over than 120 suppliers. This event is a major opportunity to exchange ideas and network with leaders in the pharmaceutical industry.

The event will feature the active participation of health authorities, ANSM, and the contribution of notified bodies such as GMED, TÜV, and BSI. These organizations will address, in particular, the challenges of Article 117 of Regulation 2017/745. This gathering is a major opportunity to engage with experts. It reaffirms that people are the indispensable strategic lever of our industry. Join us for these three days of technical and scientific high-level discussions. We look forward to sharing these moments of expertise and network with you in a consistently friendly atmosphere. It is the A3P’s historic legacy that, year after year, builds its reputation.

New EMA Sterilization Guidelines

This guide replaces the document “Decision Trees for Selection Methods” (CPMP/QWP/054/98). A draft of this text was released for consultation in April 2016. As soon as it was published, A3P established a GIC (joint interest group) to initially comment on this draft and then, after the final version was published, to provide additional information if necessary.

Injectable Combination Products: Issues and Challenges for Manufacturers

A growing need driven by innovation that benefits patients. With the rising prevalence of chronic diseases and the development of new generations of biotechnology-based drugs, the market for combination injectable products is undergoing significant change. Driven by growing demand for innovative therapeutic solutions, combination products help improve patient adherence to treatments—and thus their efficacy—while ensuring optimal ease and safety of administration.

EU MDR and IVDR Combination products are now subject to the same degree of surveillance as stand-alone medical devices.

All medical device manufacturers placing products on the market in the EU are aware of the far-reaching impact of the new Medical Devices Regulation (MDR) and/or the In Vitro Diagnostic Medical Devices Regulation (IVDR) on the European regulatory landscape. However, the impact these regulatory changes may have on pharmaceutical companies and their products is less clear.